ANAVEX LIFE SCIENCES CORP.
Business
ANAVEX LIFE SCIENCES CORP. is a clinical-stage biopharmaceutical company developing differentiated therapeutics that apply precision medicine to central nervous system (CNS) diseases with high unmet need. Its main products include small-molecule sigma‑1 receptor modulators and muscarinic modulators such as ANAVEX®2‑73 (blarcamesine) and ANAVEX®3‑71, plus additional preclinical candidates targeting neurodegenerative, neurodevelopmental, pain and oncology indications. The company organizes around clinical development and research programs that integrate genomic biomarker analysis, preclinical discovery and regulatory filings. It conducts global clinical trials and regulatory interactions across the United States, Europe, Australia, the U.K., Canada and other markets, and pursues partnerships, compassionate use and centralized regulatory pathways for commercialization.
Summary from filing dated 2025-11-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| General and administrative | 14 | 11 | 12 | 13 | 9 | |
| Research and development | 38 | 42 | 44 | 38 | 33 | |
| Total operating expenses | 51 | 53 | 56 | 51 | 42 | |
| Operating loss | −51 | −53 | −56 | −51 | −42 | |
| Grant income | 37,000 | 75,000 | 25,000 | — | 54,000 | |
| Research and development incentive income | 648,000 | 2 | 3 | 3 | 5 | |
| Interest income, net | 5 | 7 | 7 | 947,000 | 26,000 | |
| Other financing expense | — | — | −964,000 | — | — | |
| Foreign exchange gain (loss) | −332,000 | 189,000 | −40,000 | −904,000 | −266,000 | |
| Total other income, net | 5 | 10 | 8 | 3 | 4 | |
| Net loss and comprehensive loss | −46 | −43 | −48 | −48 | −38 | |
| Net Loss per share, Basic | −0.54 | −0.52 | −0.6 | −0.62 | −0.54 | |
| Net Loss per share, Diluted | −0.54 | −0.52 | −0.6 | −0.62 | −0.54 | |
| Weighted average number of shares outstanding, Basic | 85 | 83 | 80 | 77 | 70 | |
| Weighted average number of shares outstanding, Diluted | 85 | 83 | 80 | 77 | 70 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 103 | 132 | 151 | 149 | 152 | |
| Incentive and tax receivables | 809,000 | 2 | 3 | 3 | 9 | |
| Prepaid expenses and other current assets | 429,000 | 931,000 | 653,000 | 354,000 | 371,914 | |
| Total Assets | 104 | 136 | 154 | 153 | 162 | |
| Accounts payable | 4 | 10 | 4 | 4 | 5 | |
| Accrued liabilities - Note 3 | 4 | 5 | 7 | 6 | 6 | |
| Deferred grant income - Note 4 | 805,000 | 842,000 | 917,000 | 444,000 | 443,831 | |
| Total Liabilities | 9 | 15 | 13 | 10 | 11 | |
| Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share | — | — | — | — | — | |
| Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517) | 87,000 | 85,000 | 82,000 | 78,000 | 75,920 | |
| Additional paid-in capital | 477 | 456 | 435 | 388 | 348 | |
| Accumulated deficit | −382 | −336 | −293 | −246 | −198 | |
| Total Stockholders Equity | 95 | 120 | 142 | 142 | 151 | |
| Total Liabilities and Stockholders Equity | 104 | 136 | 154 | 153 | 162 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Non cash financing related charges | — | — | 845,000 | — | — | |
| Share based compensation | 12 | 9 | 16 | 18 | 8 | |
| Incentive and tax receivables | 2 | 260,000 | 484,000 | 6 | −4 | |
| Prepaid expenses and deposits | 502,000 | −278,000 | −299,000 | 1,000 | 88,000 | |
| Accounts payable | −5 | 5 | 497,000 | −914,000 | 751,000 | |
| Accrued liabilities | −943,000 | −2 | 1 | 330,000 | 2 | |
| Deferred grant income | −37,000 | −75,000 | 473,000 | — | 444,000 | |
| Net cash used in operating activities | −39 | −31 | −28 | −24 | −30 | |
| Issuance of common shares, net of share issue costs | 9 | 11 | 28 | — | — | |
| Payment for taxes related to cashless exercise of options | −3 | — | — | — | — | |
| Proceeds from exercise of stock options | 3 | 691,000 | 2 | 1 | 4 | |
| Net cash provided by financing activities | 9 | 12 | 30 | 21 | 153 | |
| (Decrease) Increase in cash and cash equivalents during the year | −30 | −19 | 2 | −3 | 123 | |
| Cash paid for state and local franchise taxes | 125,000 | 300,000 | 136,000 | — | — | |
| Common stock issued upon cashless exercise of stock options | 1 | — | — | — | — |